CD44 and central nervous system cancer: Instead, GBM molecular response to ICB appears to depend upon signatures of tumor aggressiveness (pSTAT3, PTEN, and CD44)11,30,32 and on the presence of neutrophils and myeloid cells, which have been implicated in glioma progression and treatment resistance33,34.